Gynecology Collaboration, R&D, and Licensing Deals Trends globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms.
Hyloris And Purna Female Healthcare Announce Positive Results From Phase 2 Trial In Patients With Acute Vulvovaginal Candidiasis (VVC) menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results
On track to fuel the pipeline with =4 new product candidates in 2021
Strong cash position of €64 million year-end to execute ambitious growth plan
14 commercial products expected by 2024
Conference call and
Liège, Belgium - 9 March 2021 -
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented:
I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our knowhow and innovative technol